Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 Cm and Microvascular Invasion
Launched by CHANG GUNG MEMORIAL HOSPITAL · Oct 4, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how tumor size and a specific condition called microvascular invasion affect the survival and recurrence of patients with operable solitary hepatocellular carcinoma (HCC), which is a type of liver cancer. Researchers want to find out if having a larger tumor (over 6.5 cm) has a bigger impact on a patient's outcome than the presence of microvascular invasion, where cancer cells invade small blood vessels. They will look back at medical records from January 2019 to December 2022 to analyze the results of patients who had surgery for this type of cancer.
To participate in this trial, patients must have operable solitary HCC and not have any other severe conditions affecting their cancer classification. The researchers will group participants based on their tumor size and whether they have microvascular invasion, then evaluate how these factors influence their chances of survival and cancer recurrence. Overall, this study aims to provide clearer insights into how these characteristics affect patient outcomes after surgery, which could help guide treatment decisions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Operable solitary hepatocellular carcinoma
- Exclusion Criteria:
- • Not pT1N0M0 or pT2N0M0
- • Missing tumor size
- • Errors in survival/recurrence dates or status
About Chang Gung Memorial Hospital
Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taoyuan, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported